Payment of an overdue $120m Astrazeneca milestone, plus two other obligations, has been met through a loan facility with undisclosed terms.
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
Roche awaits a high-risk, high-reward readout in autism, while for Ocular Therapeutix placebo ought to be easier to beat than active control.
The heavily promoted company’s cell therapy fails a key study in ischaemic stroke.
Some of the big small-cap fallers, meanwhile, have been subject of M&A activity. Is this a sign of things to come in 2019?
Turbulence in Japan made the country’s biopharma industry a relatively safe haven – but clinical success or setbacks dictated the fortunes of most mid and small-cap…
Limiting abuse and reducing risks are the differentiating factors for projects from Kempharm and Supernus.
The Bristol-Myers Squibb and Amicus drugs face approval decisions next week.